Tirzepatide Peptide China 99%Purity White Lyophilized powder 10vial/box Jack

 Contact us  

Product: Tirzepatide

· Specification: 5mg/vial, 10mg/vial, 15mg/vial,20mg/vial,30mg/vial,40mg/vial ,50mg/vial,60mg/vial(optional)
· Packaging: 10 vials per box
· Form: Sterile lyophilized powder (purity >99%)
· Usage: Reconstitute with bacteriostatic water before subcutaneous(for lyophilized powder).Administer once per week.
· Storage:
· Before reconstitution / unopened: Refrigerate at 2–8°C, do not freeze
· After reconstitution / after use: Can be stored at room temperature (not exceeding 30°C), protect from light. Recommended to use within 30 days.
· Price: Please contact the supplier (price varies by specification and order quantity)
· Shipping: Depends on quantity, destination, and customs policies. Typically $80 for up to 5 boxes to the US/Australia. Delivery time: 7–14 days.

What it is used for:
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It has been approved by the FDA and NMPA for the following indications:

1. Type 2 Diabetes Mellitus

· Improves blood sugar control in adults with type 2 diabetes
· Can be used alone or in combination with other antidiabetic medications (e.g., metformin, SGLT2 inhibitors, insulin)
· Reduces HbA1c by up to 2.0%–2.5%
· Significantly improves both fasting and postprandial blood glucose in some patients

2. Weight Management

· For chronic weight management in adults with obesity (BMI ≥ 28 kg/m²) or overweight (BMI ≥ 24 kg/m²) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia)
· At 72 weeks, the 15mg group achieved an average weight loss of 20.9% (approximately 24 kg)
· Reduces waist circumference, body fat percentage, and visceral fat

3. Obstructive Sleep Apnea (OSA)

· For adults with obesity and moderate-to-severe OSA
· Significantly reduces the Apnea-Hypopnea Index (AHI) and improves nocturnal hypoxia

4. Cardiometabolic Improvements

· Lowers both systolic and diastolic blood pressure
· Reduces triglycerides, LDL cholesterol, and total cholesterol
· Reduces inflammatory markers (e.g., hs-CRP)
· May reduce the risk of major adverse cardiovascular events (MACE)

5. Non-Alcoholic Fatty Liver Disease (NAFLD)

· Reduces liver fat content
· Improves liver function markers (e.g., ALT, AST)

6. Polycystic Ovary Syndrome (PCOS)

· Studies suggest improvement in insulin resistance and reduction of androgen levels
· May help restore menstrual cycles and promote ovulation (more clinical data needed)

7. Chronic Kidney Disease (CKD)

· May slow decline in kidney function through improvements in blood sugar, blood pressure, and body weight
· Potential benefit for patients with type 2 diabetes and CKD

Target audience (for reference only):

· Patients with type 2 diabetes
· Adults with obesity (BMI ≥ 28 kg/m²) or overweight (BMI ≥ 24 kg/m²) with at least one weight-related comorbidity
· Adults with obesity and moderate-to-severe OSA
· Patients with non-alcoholic fatty liver disease (NAFLD)
· Patients with polycystic ovary syndrome (PCOS) — under physician evaluation
· Must be used under the guidance of a physician

Important notes:

· Boxed Warning: Contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
· Common side effects: Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, indigestion. Mostly mild to moderate, typically diminish over time.
· Serious adverse reactions:
· Acute pancreatitis (discontinue and seek medical attention if persistent severe abdominal pain occurs)
· Gallbladder disease (cholelithiasis, cholecystitis)
· Hypoglycemia (especially when combined with sulfonylureas or insulin)
· Acute kidney injury (rare, mostly due to dehydration from severe gastrointestinal reactions)
· Not recommended for pregnant or breastfeeding women, individuals with severe gastrointestinal disorders, or those with a history of pancreatitis
· Prescription drug. Must be used under the supervision of a physician.